COMPASS PATHWAYS PLC (CMPS) Debt / Equity
- 2026-06-30: Debt/Equity Ratio 0.6.
- 2026-03-31: Debt/Equity Ratio 0.15.
- 2025-12-31: Debt/Equity Ratio -0.6.
- 2025-09-30: Debt/Equity Ratio 0.83.
Complete source-backed debt/equity ratio history.
- Available history
- 2023-12-31 to 2026-06-30
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2026-06-30 | 0.6 |
| 2026-03-31 | 0.15 |
| 2025-12-31 | -0.6 |
| 2025-09-30 | 0.83 |
| 2025-06-30 | 0.19 |
| 2025-03-31 | 0.16 |
| 2024-12-31 | 0.19 |
| 2023-12-31 | 0.13 |
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2025-12-31 | -0.6 |
| 2024-12-31 | 0.19 |
| 2023-12-31 | 0.13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |